Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Reumatol. clín. (Barc.) ; 18(7): 387-392, Ago.- Sep. 2022. tab
Artigo em Espanhol | IBECS | ID: ibc-207308

RESUMO

Antecedentes y objetivos: La artritis psoriásica se acompaña de una serie de comorbilidades cardiovasculares y metabólicas. La obesidad transcribe un estado de inflamación sistémica de bajo grado. Además, es un predictor negativo de la respuesta al tratamiento. Nuestro objetivo es evaluar si existen interacciones entre el estado metabólico, los parámetros inflamatorios y la actividad de la enfermedad. También queremos comprobar si las enfermedades metabólicas o cardiovasculares tienen alguna asociación con la reducción de la carga inflamatoria mediante el tratamiento de la enfermedad. Material y método: Hemos realizado un estudio descriptivo transversal de 160 pacientes con artritis psoriásica. Se recogieron variables sociodemográficas, clínicas y analíticas. También se registró la presencia de dactilitis y entesitis, el HAQ, DAPSA y si se cumplen o no los criterios MDA. La prueba de chi-cuadrado y la H de Kruskall Wallis se utilizaron para realizar comparaciones, considerando p<0,05 como estadísticamente significativo. Para establecer correlaciones, se utilizó el coeficiente de correlación de Pearson. Resultados: El IMC y el perímetro abdominal se correlacionan con la PCR y la VSG (significación<0,05) aunque la fuerza de correlación es baja (Pearson<0,4), pero no con DAPSA o con cumplir los criterios de MDA. El uso de terapias biológicas se asocia con una menor prevalencia de eventos cardiovasculares (p=0,047; OR: 0,12; IC 95%: 0,01-0,9) y de entesitis (p=0,008; OR: 0,3; IC 95%: 0,16-0,56). También se asocia a unos niveles normales de PCR (p=0,029; OR: 0,25; IC 95%: 0,07-0,87) y VSG (p=0,024; OR: 0,36; IC 95%: 0,16-0,82) cuando se compara con las terapias convencionales. Discusión y conclusiones: El tratamiento anti-TNFα podría reducir el riesgo cardiovascular en pacientes con artritis psoriásica. Puede haber niveles más altos de PCR y VSG en personas obesas sin que esto implique necesariamente una mayor actividad de la enfermedad.(AU)


Background and objetives: Psoriatic arthritis is accompained by several cardiometabolic comorbidities. Obesity causes a low-grade systemic inflammation and is a negative predictor of treatment response. We wanted to evaluate if there are interactions between metabolic status, inflammatory parameters and disease activity; and whether metabolic or cardiovascular diseases have any association with the reduction of the inflammatory burden by treating the psoriatic arthritis. Material and methods: We have carried out a cross-sectional descriptive study of 160 patients with psoriatic arthritis. Sociodemographic, clinical and analytical variables were collected, as well as the presence of dactylitis and enthesitis; and HAQ, DAPSA and Minimal Disease Activity criteria. Chi-square test and the H of Kruskall Wallis were used to carry out comparisons, considering P<.05 as statistically significant. To establish correlations, Pearson correlation coefficient was used. Results: BMI and waist circumference correlate with CRP and ESR (significance: <.05) although the correlation strenght is low (Pearson<.4), but there is no such relationship with DAPSA or meeting MDA criteria. Using biologic therapies is associated with a lower prevalence of cardiovascular events (P=0.047; OR: 0.12, 95% CI: 0.01-0.9) and enthesitis (P=.008; OR: 0.3, CI 95%: 0.16-0.56); and normal levels of CRP (P=.029; OR: 0.25, 95% CI: 0.07-0.87) and ESR (P=0.024; OR: 0.36, 95% CI: 0.16-0.82) when comparing to conventional therapies. Discussion and conclusions: Anti-TNFα treatment could reduce cardiovascular risk in patients with psoriatic arthritis. There may be higher levels of CRP and ESR in obese individuals without this necessarily implying higher disease activity.(AU)


Assuntos
Humanos , Masculino , Feminino , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Artrite Psoriásica/complicações , Artrite Psoriásica/epidemiologia , Artrite Psoriásica/terapia , Cardiopatias , Doenças Metabólicas , Comorbidade , Circunferência da Cintura , Índice de Massa Corporal , Terapia Biológica , Reumatologia , Epidemiologia Descritiva , Estudos Transversais
2.
Reumatol Clin (Engl Ed) ; 18(7): 387-392, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-34799299

RESUMO

BACKGROUND AND OBJETIVES: Psoriatic arthritis is accompained by several cardiometabolic comorbidities. Obesity causes a low-grade systemic inflammation and is a negative predictor of treatment response. We wanted to evaluate if there are interactions between metabolic status, inflammatory parameters and disease activity; and whether metabolic or cardiovascular diseases have any association with the reduction of the inflammatory burden by treating the psoriatic arthritis. MATERIAL AND METHODS: We have carried out a cross-sectional descriptive study of 160 patients with psoriatic arthritis. Sociodemographic, clinical and analytical variables were collected, as well as the presence of dactylitis and enthesitis; and HAQ, DAPSA and Minimal Disease Activity criteria. Chi-square test and the H of Kruskall Wallis were used to carry out comparisons, considering P < .05 as statistically significant. To establish correlations, Pearson correlation coefficient was used. RESULTS: BMI and waist circumference correlate with CRP and ESR (significance: < .05) although the correlation strenght is low (Pearson <.4), but there is no such relationship with DAPSA or meeting MDA criteria. Using biologic therapies is associated with a lower prevalence of cardiovascular events (P = 0.047; OR: 0.12, 95% CI: 0.01-0.9) and enthesitis (P = .008; OR: 0.3, CI 95%: 0.16-0.56); and normal levels of CRP (P = .029; OR: 0.25, 95% CI: 0.07-0.87) and ESR (P = 0.024; OR: 0.36, 95% CI: 0.16-0.82) when comparing to conventional therapies. DISCUSSION AND CONCLUSIONS: Anti-TNFα treatment could reduce cardiovascular risk in patients with psoriatic arthritis. There may be higher levels of CRP and ESR in obese individuals without this necessarily implying higher disease activity.


Assuntos
Artrite Psoriásica , Doenças Cardiovasculares , Artrite Psoriásica/complicações , Artrite Psoriásica/tratamento farmacológico , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/etiologia , Comorbidade , Estudos Transversais , Humanos , Obesidade/complicações , Obesidade/epidemiologia
3.
Mod Rheumatol Case Rep ; 6(1): 75-79, 2022 Jan 07.
Artigo em Inglês | MEDLINE | ID: mdl-34491342

RESUMO

The case of a 75-year-old woman diagnosed with polymyalgia rheumatica (PMR), treated with low doses of prednisone, and with clinical and analytical remission is reported. Two years later, she presented with a clinical picture of giant cell arteritis (GCA), including headache, diplopia, jaw pain, feeling of swelling in both temples, and elevation of acute phase reactants. Symptoms spontaneously subsided 2 weeks later, while analytical parameters improved without any treatment. A high-resolution colour Doppler ultrasound showed thickening of the intima-media complex with 'halo' sign in the right temporal artery. A biopsy of the right temporal artery was performed, although it was not successful, as no artery could be found, and the procedure became more complicated with an eyebrow ptosis due to a lesion in the frontal branch of the facial nerve. GCA diagnosis was based on the clinical, laboratory, and ultrasound findings. The patient was treated with prednisone and methotrexate, without clinical or analytical relapse. Comments are presented on the described cases of GCA with spontaneous remission, and the most appropriate treatments in these cases are discussed. Other peculiarities of the case, such as the progression to GCA more than 2 years after the onset of PMR, and the complications from the temporal artery biopsy are also mentioned.


Assuntos
Arterite de Células Gigantes , Polimialgia Reumática , Idoso , Feminino , Arterite de Células Gigantes/diagnóstico , Arterite de Células Gigantes/tratamento farmacológico , Humanos , Prednisona/uso terapêutico , Remissão Espontânea , Artérias Temporais/diagnóstico por imagem
4.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-34275767

RESUMO

BACKGROUND AND OBJETIVES: Psoriatic arthritis is accompained by several cardiometabolic comorbidities. Obesity causes a low-grade systemic inflammation and is a negative predictor of treatment response. We wanted to evaluate if there are interactions between metabolic status, inflammatory parameters and disease activity; and whether metabolic or cardiovascular diseases have any association with the reduction of the inflammatory burden by treating the psoriatic arthritis. MATERIAL AND METHODS: We have carried out a cross-sectional descriptive study of 160 patients with psoriatic arthritis. Sociodemographic, clinical and analytical variables were collected, as well as the presence of dactylitis and enthesitis; and HAQ, DAPSA and Minimal Disease Activity criteria. Chi-square test and the H of Kruskall Wallis were used to carry out comparisons, considering P<.05 as statistically significant. To establish correlations, Pearson correlation coefficient was used. RESULTS: BMI and waist circumference correlate with CRP and ESR (significance: <.05) although the correlation strenght is low (Pearson<.4), but there is no such relationship with DAPSA or meeting MDA criteria. Using biologic therapies is associated with a lower prevalence of cardiovascular events (P=0.047; OR: 0.12, 95% CI: 0.01-0.9) and enthesitis (P=.008; OR: 0.3, CI 95%: 0.16-0.56); and normal levels of CRP (P=.029; OR: 0.25, 95% CI: 0.07-0.87) and ESR (P=0.024; OR: 0.36, 95% CI: 0.16-0.82) when comparing to conventional therapies. DISCUSSION AND CONCLUSIONS: Anti-TNFα treatment could reduce cardiovascular risk in patients with psoriatic arthritis. There may be higher levels of CRP and ESR in obese individuals without this necessarily implying higher disease activity.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...